Date: 2011-04-11
Type of information: R&D agreement
Compound: therapeutic antibodies
Company: MorphoSys (Germany) ContraFect (USA)
Therapeutic area: Infectious diseases
Type agreement: R&D development licensing commercialisation
Action mechanism:
Disease:
Details: MorphoSys AG has formed a new alliance with US-based biotechnology company ContraFect Corp. in the discovery and development of therapeutic antibodies for infectious diseases. Under the terms of the five-year agreement, ContraFect will receive access to HuCAL PLATINUM, the latest and most powerful version of MorphoSys's antibody libraries, and AutoCAL at its facility in New York. Payments under the agreement include committed annual license fees in addition to success-based development milestones. MorphoSys also stands to receive royalties on sales of marketed drug products emerging from the collaboration.
Financial terms:
Latest news:
